Sessions

*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP02-110-21-International multicentre controlled trial to evaluate 1200mg and 1800mg rifampicin daily in the reduction of treatment duration for pulmonary TB from six to four monthsThe current treatment for drug-sensitive pulmonary tuberculosis (TB) involves taking drugs daily for six months. RIFASHORT is an international multicentre controlled clinical trial which evaluates higher doses of rifampicin with the objective of reducing the treatment duration for drug-sensitive pulmonary TB from six months to four months.
Tulika Munshi

EP02-111-21-Documenting challenges faced and lessons learned from implementation of STREAM – the world’s largest recruited multidrug-resistant TB clinical trialMulticountry clinical trial implementation is complex – from different regulatory requirements and approval processes to variable research infrastructure and capacity across settings. Here, we document challenges faced and lessons learned from STREAM – the first large-scale, multicountry clinical trial for multidrug-resistant tuberculosis.
Meera Gurumurthy

EP02-112-21-A method for baseline adjudication of TB diagnosis in children in a therapeutic clinical trial: experience from SHINEDiagnosing non-severe pulmonary tuberculosis (TB) in children is challenging.  Results in children adjudicated as having TB (in the SHINE trial comparing four vs six months of standard therapy) will be essential. The approach to adjudicate TB or not TB can help overcome challenges in paediatric TB studies in the absence of gold standard diagnostic tests.
Genevieve H Wills

EP02-113-21-Sustainability of the ACT4 randomised trial to improve initiation of TB preventive treatmentThe ACT4 randomised trial found that a health systems' intervention in strengthening management of latent tuberculosis (TB) infection was effective at increasing TB preventive therapy initiation rates in households contacts. In this follow up study, the sustainability of the ACT4 intervention was evaluated over the nine months following the end of the trial.
Olivia Oxlade

EP02-114-21-Utility of colour vision testing in screening for ethambutol-associated ocular toxicity in children treated for TB in the SHINE trialEthambutol-associated ocular toxicity (EAOT) is reported in 0.05-0.7% of children treated for tuberculosis (TB). Using a child-friendly colour vision test as a screening tool, there was no evidence of clinically significant EAOT in children taking ethambutol.  Colour vision testing in children is feasible but may not be necessary for standard drug-sensitive TB treatment.
Eric Wobudeya

EP02-115-21-Adolescents in a TB clinical treatment trial: characteristics of an under represented populationAdolescents represent approximately 10% of the global tuberculosis (TB) burden yet they are historically under represented in clinical trials, potentially limiting their access to new treatments. We examined enrolment patterns for adolescents in a TB Trials Consortium and AIDS Clinical Trials Group Phase III and rifapentine-containing treatment shortening trial for pulmonary TB (NCT02410772).
Kimberley Hedges

EP02-116-21-Investigator reported barriers and facilitators to adolescent recruitment, enrolment and retention in TB Trials Consortium Study 31/ACTG A5349In a randomised, phase III treatment shortening trial for drug-susceptible pulmonary tuberculosis, we evaluated barriers and facilitators of adolescent participation in clinical trials. Using the capability, opportunity, motivation and behaviour model, we constructed interview guides, conducted interviews with principal investigators across two research consortia and analysed interview transcripts.
Joan Mangan

EP02-117-21-Exploring antagonism in anti-TB drugs using a hollow-fiber modelIsoniazid is part of the frontline anti-tuberculosis (TB) regimen. We have shown that its inclusion in a rifampicin/isoniazid dual therapy model increases the incidence of drug-tolerant, lipid-rich cells that stain as if respiring but with a compromised cell wall. This data is indicative of clearance antagonism occurring in TB chemotherapy.
Robert Hammond